Home › Multiple Myeloma › North Carolina
Multiple Myeloma clinical trials in North Carolina
53 studies for Multiple Myeloma are looking for participants at sites in North Carolina.
Cities in North Carolina
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
- Novant Health Cancer Institute, Charlotte
- Forsythe Memorial Hospital Inc., dba Novant Health Oncology Specialists, Winston-Salem
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT07555938A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
- University of North Carolina /ID# 251203, Chapel Hill
- Atrium Health Wake Forest Baptist Medical Center /ID# 251165, Winston-Salem
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT05650632A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
- University of North Carolina at Chapel Hill, Chapel Hill
- Wake Forest University Health Sciences, Winston-Salem
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT05137054A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- Levine Cancer Institute, Charlotte
RecruitingPhase 4
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT05201781A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
- Wake Forest University Baptist Medical Center (WFUBMC) - Comprehensive Cancer Center, Winston-Salem
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Nov 3, 2026 · NCT07149857A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Levine Cancer Institute, Charlotte
- Novant Health, Charlotte
- Durham VAMC, Durham
- and 3 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT05552222A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
- Levine Cancer Institute, Charlotte
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT05652335A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- University of North Carolina, Chapel Hill
- Durham VAMC, Durham
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT07258511Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
- University of North Carolina Hospitals at Hillsborough, Chapel Hill
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 30, 2026 · NCT06433947A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
- UNC Hospitals Adult Oncology Clinics, Chapel Hill
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 30, 2026 · NCT07284758A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
- Duke Cancer Center, Durham
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 30, 2026 · NCT07280013A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
- Levine Cancer Institute, Charlotte
- Levine Cancer Institute, Charlotte
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 29, 2026 · NCT06615479Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
RecruitingObservational study
Ages 18 to 120 · All sexes · Updated Oct 28, 2026 · NCT01137643A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
- Atrium Health Levine Cancer Institute /ID# 271510, Charlotte
- University Of North Carolina Health Care - Hillsborough Campus /ID# 272454, Hillsborough
- Atrium Health Wake Forest Baptist Medical Center /ID# 271294, Winston-Salem
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 27, 2026 · NCT06953960Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
- Levine Cancer Institute, Charlotte
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 26, 2026 · NCT04822337Neurocognitive Trajectories After BCMA CAR-T
- Atrium Health Levine Cancer, Charlotte
RecruitingObservational study
Ages 18 and older · All sexes · Updated Oct 23, 2026 · NCT07740317A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
- Atrium Health, Levine Cancer Institute, Charlotte
- Duke University Hospital, Durham
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 22, 2026 · NCT05651932Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study
- Wake Forest University, School of Medicine Dept. of Internal Medicine, Division of Hematology Oncology, Winston-Salem
RecruitingPhase 2
Ages 60 and older · All sexes · Updated Oct 22, 2026 · NCT06052826A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
- Research Site, Chapel Hill
- Research Site, Charlotte
- Research Site, Durham
- and 1 more
RecruitingPhase 3
Ages 18 to 130 · All sexes · Updated Oct 21, 2026 · NCT07735637A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
- University of North Carolina at Chapel Hill /ID# 274667, Chapel Hill
- Atrium Health Levine Cancer Institute /ID# 276193, Charlotte
- Atrium Health Wake Forest Baptist Medical Center /ID# 274847, Winston-Salem
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 19, 2026 · NCT06892522A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
- University of North Carolina at Chapel Hill /ID# 277708, Chapel Hill
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Oct 19, 2026 · NCT07095452Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Duke University, Durham
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 14, 2026 · NCT07648264AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
- Research Site, Charlotte
- Research Site, Durham
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 8, 2026 · NCT05850234Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- University of North Carolina Medical Center, Chapel Hill
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 6, 2026 · NCT06297226A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Research Site, Chapel Hill
- Research Site, Charlotte
- Research Site, Charlotte
- and 2 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT07391657A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Duke University Medical Center, Durham
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07518186A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
- Duke University Medical Center, Durham
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06500884A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
- Atrium Health Levine Cancer Institute, Charlotte
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT07116616TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Lineberger Comprehensive Cancer Center, Chapel Hill
- Atrium Health's Levine Cancer Institute, Charlotte
RecruitingPhase 2
Ages 12 and older · All sexes · Updated Sep 22, 2026 · NCT02693535HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM
- Duke University Health System, Durham
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT06822972Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
- University of North Carolina Hospitals at Hillsborough, Hillsborough
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT06375044Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- Southeastern Medical Oncology Center-Clinton, Clinton
- Southeastern Medical Oncology Center-Goldsboro, Goldsboro
- Southeastern Medical Oncology Center-Jacksonville, Jacksonville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT04566328A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
- GSK Investigational Site, Chapel Hill
- GSK Investigational Site, Wilson
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT05714839DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
- Lineberger Comphrehensive Cancer Center at University of North Carolina, Chapel Hill
Recruiting
Ages 60 and older · All sexes · Updated Aug 14, 2026 · NCT06296368Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, Chapel Hill
- Research Site, Charlotte
- Research Site, Durham
- and 2 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 14, 2026 · NCT07764978Selinexor and Backbone Treatments of Multiple Myeloma Patients
- Duke Institute of Cancer/ Duke University, Durham
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 15, 2026 · NCT02343042Pre-malignant States to Hematologic Malignancies in Firefighters
- Levine Cancer Institute, Charlotte
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 49 · All sexes · Updated Jul 13, 2026 · NCT06870760CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study
- Atrium Health Levine Cancer, Charlotte
RecruitingObservational studyHealthy volunteers welcome
Ages 30 and older · All sexes · Updated Jul 13, 2026 · NCT06644625A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
- University of North Carolina (Data Collection Only), Chapel Hill
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 6, 2026 · NCT06083922Registry of Older Patients With Cancer
- Seby B. Jones Cancer Center, Boone
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
- East Carolina University, Greenville
- and 4 more
RecruitingObservational study
Ages 65 and older · All sexes · Updated Jun 29, 2026 · NCT01137825From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.